A phase I study of lapatinib with whole brain radiotherapy in patients with Human Epidermal Growth Factor Receptor 2 (HER2)-positive breast cancer brain metastases (Q39320080)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	A phase I study of lapatinib with whole brain radiotherapy in patients with Human Epidermal Growth Factor Receptor 2 (HER2)-positive breast cancer brain metastases	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

11 September 2017

A phase I study of lapatinib with whole brain radiotherapy in patients with Human Epidermal Growth Factor Receptor 2 (HER2)-positive breast cancer brain metastases (English)

1 reference

Europe PubMed Central

11 September 2017

Adaptive radiation therapy

0 references

16

object named as

Beverly Moy

1 reference

Europe PubMed Central

11 September 2017

18

object named as

Eric P Winer

1 reference

Europe PubMed Central

11 September 2017

Jennifer Ligibel

14

object named as

Jennifer A Ligibel

1 reference

Europe PubMed Central

11 September 2017

1

object named as

Nancy U Lin

1 reference

Europe PubMed Central

11 September 2017

Rachel A Freedman

2

object named as

Rachel A Freedman

1 reference

Europe PubMed Central

11 September 2017

Jennifer R Bellon

6

object named as

Jennifer R Bellon

1 reference

Europe PubMed Central

11 September 2017

4

object named as

Jerry Younger

1 reference

Europe PubMed Central

11 September 2017

Emily Eisenberg

13

object named as

Emily Eisenberg

1 reference

Europe PubMed Central

11 September 2017

Naren Ramakrishna

3

object named as

Naren Ramakrishna

1 reference

Europe PubMed Central

11 September 2017

author name string

Anna Maria Storniolo

5

1 reference

Europe PubMed Central

11 September 2017

Steven E Come

7

1 reference

Europe PubMed Central

11 September 2017

Rebecca S Gelman

8

1 reference

Europe PubMed Central

11 September 2017

Gordon J Harris

9

1 reference

Europe PubMed Central

11 September 2017

Mark A Henderson

10

1 reference

Europe PubMed Central

11 September 2017

Shannon M Macdonald

11

1 reference

Europe PubMed Central

11 September 2017

Anand Mahadevan

12

1 reference

Europe PubMed Central

11 September 2017

Erica L Mayer

15

1 reference

Europe PubMed Central

11 September 2017

April F Eichler

17

1 reference

Europe PubMed Central

11 September 2017

language of work or name

0 references

publication date

7 November 2013

1 reference

Europe PubMed Central

11 September 2017

Breast Cancer Research and Treatment

1 reference

Europe PubMed Central

11 September 2017

142

1 reference

Europe PubMed Central

11 September 2017

2

1 reference

Europe PubMed Central

11 September 2017

405-414

1 reference

Europe PubMed Central

11 September 2017

https://scigraph.springernature.com/pub.10.1007/s10549-013-2754-0

0 references

Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2754-0

21 January 2018

CNS relapses in patients with HER2-positive early breast cancer who have and have not received adjuvant trastuzumab: a retrospective substudy of the HERA trial (BIG 1-01).

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2754-0

21 January 2018

Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2754-0

21 January 2018

Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2754-0

21 January 2018

Lapatinib plus capecitabine for HER2-positive advanced breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2754-0

21 January 2018

Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2754-0

21 January 2018

Her-2 overexpression increases the metastatic outgrowth of breast cancer cells in the brain

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2754-0

21 January 2018

Effect of lapatinib on the outgrowth of metastatic breast cancer cells to the brain

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2754-0

21 January 2018

Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2754-0

21 January 2018

Effects of the EGFR/HER2 kinase inhibitor GW572016 on EGFR- and HER2-overexpressing breast cancer cell line proliferation, radiosensitization, and resistance

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2754-0

21 January 2018

Mechanisms of disease: Radiosensitization by epidermal growth factor receptor inhibitors

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2754-0

21 January 2018

Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2754-0

21 January 2018

Phase I dose escalation and pharmacokinetic study of lapatinib in combination with trastuzumab in patients with advanced ErbB2-positive breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2754-0

21 January 2018

CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2754-0

21 January 2018

The Mini-Mental State Examination.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2754-0

21 January 2018

The Functional Assessment of Cancer Therapy (FACT) scale. Development of a brain subscale and revalidation of the general version (FACT-G) in patients with primary brain tumors.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2754-0

21 January 2018

The development and psychometric validation of a brain cancer quality-of-life questionnaire for use in combination with general cancer-specific questionnaires

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2754-0

21 January 2018

“Mini-mental state”

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2754-0

21 January 2018

A meta-analysis evaluating stereotactic radiosurgery, whole-brain radiotherapy, or both for patients presenting with a limited number of brain metastases

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2754-0

21 January 2018

Whole brain radiotherapy with radiosensitizer for brain metastases

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2754-0

21 January 2018

Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2754-0

21 January 2018

Concurrent capecitabine and whole-brain radiotherapy for treatment of brain metastases in breast cancer patients.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2754-0

21 January 2018

Prospective comparison of the prognostic utility of the Mini Mental State Examination and the Montreal Cognitive Assessment in patients with brain metastases.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2754-0

21 January 2018

Central Nervous System Metastases in HER-2 Positive Metastatic Breast Cancer Patients Treated with Trastuzumab: Incidence, Survival, and Risk Factors

1 reference

https://api.crossref.org/works/10.1007%2FS10549-013-2754-0

21 January 2018

Identifiers

10.1007/S10549-013-2754-0

1 reference

Europe PubMed Central

11 September 2017

1 reference

Europe PubMed Central

11 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39320080&oldid=2117164995"